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Rheumatoid arthritis is a common severe joint disease 
that affects all age groups, it is thus of great importance 
to develop new strategies for its treatment. The aim of 
the present study was to examine the combined effect 
of coenzyme Q10 (CoQ10) and methotrexate (MTX) on the 
progression of  adjuvant-induced arthritis in rats. Adju-
vant arthritis (AA) was induced by a single intradermal 
injection of heat-inactivated Mycobacterium butyricum in 
incomplete Freund’s adjuvant. The experiments included 
healthy animals, arthritic animals not treated, arthritic 
animals treated with CoQ10, with methotrexate, and with 
a combination of CoQ10 and methotrexate. The two lat-
ter groups received a daily oral dose of 20 mg/kg b.w. of 
CoQ10, either alone or with methotrexate in an oral dose 
of 0.3 mg/kg b.w. twice a week. We found that CoQ10 
potentiated both the antiarthritic (decrease of hind paw 
volume) and the antioxidant effect of methotrexate on 
the level of oxidation of proteins (suppression of pro-
tein carbonyl level in plasma) as well as lipoperoxidation 
(suppression of levels of HNE-adducts and MDA-adducts 
to plasma proteins). The same effect was observed for 
plasmatic levels of CoQ9 and IL-1α, and partially also 
for γ-glutamyltransferase activity assessed in joints and 
spleen. Moreover, the combination therapy improved 
the functionality of peripheral blood neutrophils in 
AA, with a balancing effect on the immunosuppression 
caused by MTX monotherapy. In summary, combined ad-
ministration of CoQ10 and methotrexate suppressed ar-
thritic progression in rats more effectively than did MTX 
alone. This finding may help improve treatment of rheu-
matoid arthritis.
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INTRODUCTION
Rheumatoid arthritis (RA) is a common severe joint 
disease affecting all age groups. It is thus of great im-
portance to develop new strategies for its treatment. 
As a number of disease-modifying anti-rheumatic drugs 
(DMARDs) often have side effects at high doses and/
or during long-term administration, increased efficacy 
without increased toxicity are expected for combination 
therapy of RA. Methotrexate (MTX), a folic acid antago-
nist, has become the predominant immunosuppressive 
agent used in the treatment of patients with RA (Wil-
liams et al., 1985). MTX acts mainly on actively prolifer-
ating cells during the S-phase of proliferation, suppresses 
macrophage function, modulates interleukin-1 (IL-1) and 
superoxide anion production, and inhibits neutrophil 
chemotaxis (Moreland et al., 1997). Furthermore, MTX 
treatment was shown to decrease synovial collagenase 
gene expression in patients with RA (Genestier et al., 
2000). The use of MTX has been limited by some of 
its toxic manifestations, such as abdominal discomfort, 
alopecia, oral ulcerations, and cytopenia (Alarcon et al., 
1989). In clinical studies, infliximab or etanercept have 
been used in combination with methotrexate to pro-
duce greater efficacy of the treatment of RA (Maini et 
al., 1998; Weinblatt et al., 1999). TNFα blockers may be 
used alternatively with other candidates for RA combi-
nation therapy. The lack of thorough understanding of 
the pathogenesis of RA is a major problem in the intro-
duction of new therapies. Several clinical studies as well 
as preclinical animal models of RA have documented an 
imbalance in the body redox homeostasis to a more pro-
oxidative environment, suggesting that therapies that re-
store the redox balance may have beneficial effects (Kun-
sch et al., 2005). Bauerova and Bezek (1999) and Jaswal 
et al. (2003) described oxidative stress as a primary factor 
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involved in the pathogenetic changes during rheumatoid 
arthritis. In our studies, synthetic and natural substances 
with antioxidant activity were evaluated by using adju-
vant arthritis (AA) — an animal model of RA which al-
lows monitoring the disease processes in the acute (days 
14–21) and subchronic phase (after day 28). The advan-
tage of this model is its great similarity to RA, such as 
symmetrical joint involvement, persistent joint inflamma-
tion, synovial hyperplasia, and a good response to most 
therapies effective in RA (Bina & Wilder, 1999). Many 
of the substances with antioxidant properties tested in 
monotherapy proved to be effective in suppressing the 
progression of AA (Bauerova et al., 2005a; 2005b; 2008a; 
2008b; 2009; Drabikova et al., 2009; Gvozdjakova et al., 
2004; Jancinova et al., 2009; Kogan et al., 2005; Nosal et 
al., 2007; Rovensky et al., 2008; 2009a; Sotnikova et al., 
2008; 2009).
Based on our results with mitochondrial energetics 
modification and the observed anti-inflammatory and 
antioxidant effects (Gvozdjakova et al., 2004; Bauerova 
et al., 2005a; 2008a; Ponist et al., 2007), we chose CoQ10 
as a candidate for combinatory therapy of RA. Patients 
with RA often suffer muscle weakness and atrophy. 
It is assumed that progressive muscle atrophy in RA 
patients is caused by damaged myofibrils and impaired 
mitochondria (De Palma et al., 2000). Disruption of mi-
tochondrial bioenergetics caused by free radicals is in-
volved in development of myopathies. Oxidative stress-
caused alteration of mitochondrial functions can mani-
fest in different manners (Cardoso et al., 1999). Leak-
age of free radicals from the respiratory chain leads to 
damaged mitochondrial membrane, proteins, DNA and 
inhibits oxidative phosphorylation (Luft, 1995; Miesel 
et al., 1996). Maneiro et al. (2003) found inhibition of 
functions of complex II and III of the respiratory chain 
and higher frequency of energetically “exhausted” mito-
chondria in chondrocytes of patients with osteoarthri-
tis compared to healthy donors. Following those find-
ings, we decided to support the impaired mitochondrial 
functions by CoQ10 supplementation and also reduce 
the increased oxidative stress in AA. CoQ10, a lipophilic 
antioxidant, has many protective functions which could 
be helpful in arthritic diseases: membrane stabilizing 
properties, protection of DNA against free radical dam-
age, and ability to regenerate other important antioxi-
dants as tocopherol and ascorbate (Crane, 2001). Some 
evidence from the literature showed that anti-rheumatic 
therapies which increased the level of CoQ10 were able 
to slow down RA progression (Comstock et al., 1997; 
Knekt et al., 2000; Kucharská et al., 2005). Hind paw 
muscle of arthritic animals lies very close to the in-
flamed joint and could be also sensitive to joint inflam-
mation (Ponist et al., 2007). Moreover, AA is a systemic 
inflammatory disease and we might expect also impair-
ment in myocardial mitochondria functions, which we 
indeed demonstrated in our previous experiments. We 
found that the reactions of skeletal muscle and myocar-
dium muscle on CoQ supplementation in AA were dif-
ferent, which was not so surprising in view of their dif-
ferent structure and functions in the organism (Gvozd-
jáková et al., 2007). Our experiments confirmed CoQ 
as a good antioxidant in AA showing no side effects 
even at the high dose of 200 mg/kg b.w. Thus CoQ 
administration could be an appropriate supplement to 
a basal anti-rheumatic therapeutic regimen. The aim of 
the present study was to examine the combined effect 
of CoQ10 and methotrexate on the progression of  ad-
juvant-induced arthritis in the rat. For this purpose, we 
used monitoring of hind paw volume (HPV) — a basic 
clinical parameter — along with evaluation of oxidative 
stress and inflammation markers assessed in plasma and 
tissues. 
MATERIAL AND METHODS
Animals, experimental design and treatments. 
Male Lewis rats weighing 160–180 g were obtained from 
the Breeding Farm Dobra Voda (Slovakia). The rats had 
free access to standard pelleted diet and tap water. The 
animal facilities comply with the European Convention 
for the Protection of Vertebrate Animals Used for Ex-
perimental and Other Purposes. The experimental pro-
tocol was approved by the Ethics Committee of the 
Institute of Experimental Pharmacology and Toxicology 
and by the Slovak State Veterinary Committee of Animal 
Experimentation. Adjuvant arthritis (AA) was induced 
by a single intradermal injection of heat-inactivated Myco-
bacterium butyricum (MB) in incomplete Freund’s adjuvant 
(Difco Laboratories, Detroit, MI, USA). The injection 
was performed near the tail base. The experiments in-
cluded healthy animals (HC), arthritic animals not treated 
(AA), arthritic animals treated with coenzyme Q10 (AA-
CoQ10), arthritic animals treated with methotrexate (AA-
MTX), and arthritic animals treated with the combina-
tion of CoQ10 and methotrexate (AA-MTX+CoQ10). The 
two latter groups received a daily oral dose of 20 mg/
kg b.w. of CoQ10 either alone (AA-MTX) or with meth-
otrexate in the oral dose of 0.3 mg/kg b.w. twice a week 
(AA-MTX+CoQ10). AA-MTX was performed as a refer-
ence treatment. Methotrexat® Lachema 50 sol. inj. was 
used. CoQ10 in the form of Li-Q-Sorb® was purchased 
from Tishcon Corp. (USA). In each experimental group, 
8–10 animals were used. The duration of the experiment 
was 28 days. Blood was collected under light ketamin/
xylasine anesthesia from the retro-orbital plexus on day 
7 and immediately flow cytometric measurements were 
performed. After the animals had been sacrificed un-
der deep ketamin/xylasine anesthesia, blood for plasma 
preparation and tissues for spleen and for hind paw joint 
homogenate preparation were taken on day 28. Plasma 
was stored at –70 °C until biochemical and immunologi-
cal analysis.
Clinical parameter evaluated: hind paw volume. 
We monitored one basic clinical parameter: the hind paw 
volume (HPV). The HPV increase was calculated as the 
percentage increase in the HPV on  a given experimental 
day relative to the HPV at the beginning of the experi-
ment. Hind paw volume was recorded on days 1, 14, 21, 
and 28 with the use of an electronic water plethysmom-
eter (UGO BASILE, Comerio-Varese, Italy). 
Biochemical and immunological analysis. Protein 
carbonyl assay. Enzyme linked immunosorbent as-
say (ELISA) was used for quantitative determination of 
protein carbonyls in plasma (Buss et al., 1997). Protein 
samples were derivatized with dinitrophenylhydrazine 
(DNPH) and adsorbed in multiwell plates (Nunc Immu-
nosorp plates, Roskilde, Denmark). A biotin-conjugated 
anti-dinitrophenyl rabbit IgG (Sigma, USA) was used as 
the primary antibody and a peroxidase conjugated mono-
clonal anti-rabbit-IgG antibody (Sigma, USA) as the sec-
ondary antibody. The development was performed with 
ortho-phenylendiamine. Absorbance was determined at 
492 nm. The method was calibrated using oxidized bo-
vine serum albumin (BSA). Oxidized and reduced BSA 
was prepared according to the method of Buss et al. 
(1997).
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Determination of lipid peroxidation. The pres-
ence of oxidative damage was assessed in plasma by 
determining the fluorescent adducts formed between 
peroxidation-derived aldehydes and plasma proteins. In 
particular, two types of protein-aldehyde adducts were 
determined: HNE-protein adducts (355 nm excitation; 
460 nm emission) and MDA-protein adducts (390 nm 
excitation; 460 nm emission). Preparation of samples and 
fluorimetric measurements were performed according 
to Tsuchida et al. (1985) and Biasi et al. (1995). Briefly, 
150 µl of plasma was suspended in 6 ml ethanol/ether 
(3 : 1, v : v); after 10 min incubation in ice, the samples 
were centrifuged at 1500 × g, the supernatant discarded 
and the pellets washed twice with ethanol/ether (3 : 1, 
v : v).  After the last centrifugation the pellets were dis-
solved in 3 ml of 0.1 % sodium dodecyl sulfate (SDS) 
and immediately used for spectrofluorimetry (Kontron 
SFM 25). In parallel, standard curves were prepared with 
decreasing amounts of HNE or MDA dissolved in BSA 
(1 mg/ml): the adducts aldehydes with BSA were al-
lowed to form by incubating the solutions at 37 °C for 
40 min, after which the samples were immediately read 
for fluorescence. Data were expressed as arbitrary units/
mg protein. Protein detection was done with the Peter-
son method (Peterson et al., 1977).
Coenzyme Q9 determination. Concentration of oxi-
dized coenzyme Q9 was determined by isocratic high-
performance liquid chromatography (HPLC, LKB, Swe-
den) according to Lang et al. (1986) with some modifica-
tions (Kucharska et al., 1998). Plasma samples (500 μl) 
were vortexed twice for 5 min with 2 ml of a mixture of 
hexane/ethanol (5 : 2, v/v; Merck, Germany). Collected 
organic layers were evaporated under nitrogen; the resi-
due was taken up in ethanol and injected into a Separon 
SGX C18 7 μm 3 mm × 150 mm column (Tessek, Czech 
Republic). Elution was performed with methanol/ac-
etonitrile/ethanol (6 : 2 :2, by vol.; Merck, Germany). The 
concentration of coenzyme Q9 was determined spectro-
photometrically at 275 nm, using external standards (Sig-
ma, Germany). Data were collected and processed us-
ing a CSW 32 chromatographic station (DataApex Ltd, 
Czech Republic). Concentrations of compounds in the 
plasma were calculated in μmol · l–1.
Rat IL-1α assay. For determination of IL-1α in plas-
ma an ELISA kit from Bender MedSystems was used 
as described in the product manual Rat IL-1α ELISA 
BMS627 and BMS627TEN. The rat IL-1 ELISA is an 
assay for quantitative detection of rat IL-1. Rat IL-1 
present in the samples binds to anti-rat IL-1 antibodies 
adsorbed to the microwells. The reaction of a secondary 
biotin-conjugated anti-rat IL-1 antibody is evaluated by 
Streptavidin-HRP. Tetramethylbenzidine oxidation with 
HRP bound to the immune complex was measured at 
490 nm againts reference wavelength of 620 nm. The re-
sults were calculated from a standard calibration curve 
obtained for internal standards.
Tissue activity of cellular γ-glutamyltransferase. 
The activity of cellular γ-glutamyltransferase (GGT) in 
hind paw joint tissue and in spleen tissue homogenates 
was measured by the method of Orlowski and Meister 
(1970) as modified by Ondrejickova et al. (1993). Sam-
ples were homogenized in a buffer at 1 : 9 (w/v) (buffer 
composition: 2.6 mM NaH2PO4, 50 mM Na2HPO4, 15 
mM EDTA, 68 mM NaCl; pH 8.1) by Ultra Turax TP 
18/10 (Janke & Kunkel, Germany) for 1 min at 0 °C. 
Substrates (8.7 mM γ-glutamyl-p-nitroanilide (γ-GPN); 44 
mM methionine) were added in 65 % isopropylalcohol to 
final concentrations of 2.5 mM and 12.6 mM,  respec-
tively. After incubation for 60 min at 37 °C, the reaction 
was stopped with 2.3 ml cold methanol and the tubes 
were centrifuged for 20 min at 5000 rpm. Absorbance of 
supernatant was measured in a  Hewlett Packard Vectra 
286/12 spectrophotometer in 0.5 cm cuvette at 406 nm. 
Reaction mixtures in the absence of either the substrate 
or acceptor were used as reference samples.
Simultaneous phagocytosis and oxidative burst. 
Throughout phagocytosis accompanied by respiratory 
burst of rat granulocytes, the double fluorescence of 
fluorescein isothiocyanate (FITC)-labeled ingested Sta-
phylococcus aureus cells and that of hydroxyethidine (HE) 
oxidized to ethidium bromide were evaluated by flow 
cytometry (Beckman-Coulter FC 500 flow cytometer 
running under CXP software). The previously reported 
method (Kronek et al., 2010) was modified for whole rat 
blood. For each blood sample, a fluorescence histogram 
of 5 000 cells was generated and analyzed. Gates were 
set around granulocytes to exclude debris. Measurement 
of phagocytosis, i.e. the ingestion of bacteria, took place 
under controlled conditions, using fluorescein-labeled op-
sonized  Staphylococcus aureus (SPA-FITC) (Invitrogen Mo-
lecular Probes, USA). Metabolic activity was determined 
as the oxidative burst causing transformation of the orig-
inally non-fluorescent hydroxyethidine (Invitrogen Mo-
lecular Probes, USA) into ethidium following SPA-FITC 
ingestion. Aliquots of rat peripheral blood in lithium-
heparin were incubated with HE (15.75 mg in 5 ml of 
dimethylformamide) for 15 min at 37 oC. Following treat-
ment with SPA-FITC for the next 15 min at 37 oC, the 
reaction was stopped by placing the samples on ice. The 
subsequent erythrocyte lysis was performed for  15 min 
with an ice-cold ammonium-chloride-potassium chloride 
(ACK) lysis buffer (200 ml deionized water, 1.658 g 
NH4Cl; 0.2 g KHCO3; 7.4 mg Na2EDTA, pH 7.2–7.4) 
(Lachema, Czech Republic). Blood specimens were ob-
tained by retroorbital sinus puncture under light anesthe-
sia (ketamine/xylazine) of animals. Whole blood samples 
were collected into lithium heparin (Sarstedt Multivette) 
blood sample collectors. 
Statistics. The data were expressed as arithmetic 
mean ± S.E.M. Arthritis group untreated was compared 
with healthy control animals (*), treated arthritis groups 
were compared with untreated arthritis animals (+), and 
arthritis groups with combination therapy were com-
pared with the reference treatment (#). For significance 
calculations unpaired Student’s t-test (two sample, un-
equal variance) was used with the following significance 
designations: extremely significant (p < 0.001); highly sig-
nificant (p < 0.01); significant (p < 0.05); not significant 
(p > 0.05).
RESULTS AND DISCUSSION
Clinical manifestation of adjuvant arthritis and effects 
of therapy
We monitored the hind paw volume change after clin-
ical development of arthritis on experimental days 14, 21 
and 28. In our previous experiments, we confirmed that 
clinical parameters, such as hind paw volume and body 
weight, became significantly modified starting around day 
14 (Bauerova et al., 2007). As illustrated in Fig. 1, the 
HPV is significantly increased for the arthritis group in 
comparison with healthy control already on day 14 and 
this increase is maintained until the end of the experi-
ment. CoQ10 supplementation to arthritis animals slight-
ly decreased the HPV on all experimental days. In the 
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treatment of RA, methotrexate (MTX) is the most com-
monly prescribed disease-modifying anti-rheumatic drug. 
It has suppressive effects on inflammation in AA, first 
described by Welles et al. (1985). In the present study, 
the decreasing effect of MTX monotherapy on hind paw 
swelling was evident on all monitored days (Fig. 1). The 
significance of this effect was a confirmation of its well-
known antiarthritic effect, which we proved also previ-
ously on the adjuvant arthritis model (Nosal et al., 2007; 
Jurcovicova et al., 2009; Rovensky et al., 2009c). Due to 
the adverse effects of MTX accompanying its admin-
istration to arthritic patients, which are factors often 
limiting the acceptable dose, duration and safety of the 
therapy with MTX (Visser & van der Heijde, 2009), a 
combinatory therapy of MTX is recommended with the 
aim to eliminate or minimalize these limitations. Be-
sides the classical antirheumatics given in the combina-
tion schedule with a low dose of MTX, new candidates 
with antioxidative properties are being studied (Rovensky 
et al., 2002; 2008; 2009a; 2009b; Cuzzocrea et al., 2005; 
Dadhania et al., 2010; Kogure et al., 2010). As the patho-
genesis of arthritis is associated predominantly with the 
formation of free radicals at the site of inflammation, we 
chose CoQ10 as an appropriate candidate. Antirheumatic 
treatment affecting the level of CoQ10 was found to slow 
down the progression of the disease in arthritic patients 
(Comstock et al., 1997; Knekt et al., 2000). Mitochondrial 
function in the heart and skeletal muscle and efficacy of 
supplementation with CoQ10 depended on the severity 
of the induced adjuvant arthritis (AA) in rats. The results 
with solubilized CoQ10 (water-soluble form) indicated 
its therapeutic effect in the experimental model of AA 
(Gvozdjakova et al., 2004; Bauerova et al., 2005a; 2008a; 
Ponist et al., 2007). These findings are of potential sig-
nificance in the treatment of patients with rheumatoid 
arthritis. On the basis of the results achieved with CoQ10 
monotherapy, we selected this endogenous antioxidant 
with the aim to establish its suitability for the combina-
tion with MTX. The selected oral doses (for MTX 0.3 
mg/kg of b.w. twice a week and for CoQ10 20 mg/kg 
of b.w. daily over one month) were established previ-
ously (Bauerova et al., 2005a; Jurcovicova et al., 2009). As 
shown in Fig. 1, the combination therapy was the most 
effective in decreasing the HPV of arthritic animals on 
all experimental days selected. Moreover, for day 14, we 
found a statistically significant difference between MTX 
monotherapy and its combination with CoQ10.
Different parameters of oxidative stress monitored in 
adjuvant arthritis and effect of treatment
These promising clinical results were further com-
pleted by measurements of HNE- and MDA-protein 
adducts and protein carbonyls in plasma (Fig. 2). We 
obtained a good agreement of HPV with the param-
eters of oxidative stress: the effect was increasing in the 
order CoQ10 alone, MTX alone, combination of CoQ10 
and MTX. The most pronounced effect found for the 
combination of MTX and CoQ10 was significant for all 
oxidative stress parameters compared with non-treated 
arthritic animals. Moreover, the combination decreased 
all parameters close to the control group values, being 
more effective than the individual substances (Fig. 2). 
On using measurements of plasmatic protein carbonyls, 
we found damage of proteins caused by oxidative stress 
accompanying arthritis in past experiments (Bauerova 
et al., 2005b; Kogan et al., 2005; Strosova et al., 2009). 
Progression of lipid peroxidation in AA was previously 
described by analysis of TBARS plasmatic levels (Bauer-
ova et al., 2005a; 2008b; 2009; Bauerova & Bezek, 2009; 
Strosova et al., 2008; 2009). Although the percentage in-
crease was not so high for adducts as for protein car-
bonyls and TBARS levels in plasma, advanced measure-
ments of HNE- and MDA-protein adducts showed for 
non-treated arthritis damaged animals the same level of 
significance as found for protein carbonyls (Fig. 2).
Significant changes in the levels of CoQ9  and/or 
CoQ10 have been noted in a wide variety of diseases in 
both animal and human studies. These changes may be 
caused by impairment in CoQ biosynthesis or exces-
sive utilization of CoQ by the body, or any combina-
tion of these processes (Littarru et al., 1991; Bauerova et 
al., 2008a). In this experiment, we focused on evaluating 
the CoQ9 plasmatic levels as the dominant form of CoQ 
in rats. Its concentration is about 10 times higher than 
the concentration of CoQ10 (Dallner & Sindelar, 2000). 
Figure 1. Time profile of hind paw volume
Effects of CoQ10 and methotrexate in monotherapy and combined 
therapy on the progression of adjuvant arthritis. Change in hind 
paw swelling in all experimental groups was recorded on days 
1, 14, 21, and 28 of AA and calculated as percentage of increase: 
[(Day n) / (Day 1)]×100 = [%]. The data were expressed as arithme-
tic mean ± S.E.M. Each group contained 8–10 animals. Statistical 
significance was evaluated applying Student’s t-test for independ-
ent variables: ***P < 0.001 with respect to control healthy animals; 
++P < 0.01, and +++P < 0.001 with respect to untreated arthritic ani-
mals; #P < 0.05 for comparison of methotrexate monotherapy with 
combined therapy.
Figure 2. Comparison of oxidative stress parameters assessed 
in plasma on day 28 of adjuvant arthritis
Effects of CoQ10 and methotrexate in monotherapy and combined 
therapy on oxidative stress occurring in adjuvant arthritis.
Oxidative stress parameters were measured in plasma by using 
ELISA and fluorimetric methods. Changes in all groups with arthri-
tis were calculated with respect to the control value assessed for 
healthy control animals on experimental day 28. The dashed line 
represents the value of control as 100%. The data were expressed 
as arithmetic mean ± S.E.M. Each group contained 8–10 animals. 
Statistical significance was evaluated applying Student’s t-test for 
independent variables: ***P < 0.001 with respect to control healthy 
animals; +P < 0.05, ++P < 0.01, and +++P < 0.001 with respect to un-
treated arthritic animals; #P < 0.05 and ###P < 0.001 for comparison 
of methotrexate monotherapy with combined therapy.
Vol. 57       351Combined methotrexate and coenzyme Q10 therapy
As shown in Fig. 3, the arthritis process increases sig-
nificantly the level of CoQ9 in comparison with HC. The 
effect of therapy on this phenomenon unveils a picture 
comparable to that found for other oxidative stress pa-
rameters (Fig. 2). The combination therapy was again the 
most effective and significant in comparison to the un-
treated arthritis group (Fig. 3). The improvement is on 
the level of HC. Evidently, the arthritic processes stimu-
late the synthesis of CoQ and its transport to plasma. 
These results are in good agreement with the results 
obtained on rat experimental diabetes models, in which 
increased concentrations of CoQ9 in plasma may indi-
cate adaptive changes in diseases associated with oxida-
tive stress (Kucharska et al., 2000; Kuzelova et al., 2008). 
Supplementation with CoQ10 is not sufficient to inhibit 
these processes, while the combination of CoQ10 with 
MTX proved successful in returning the increased plas-
matic levels of CoQ9 to control levels (Fig. 3).
Changes in plasma pro-inflammatory cytokine IL-1 
levels
For further evaluation of the efficacy of the admin-
istration of CoQ10+MTX, and with the aim to support 
the obtained clinical and biochemical data with immu-
nological measurements, we performed an analysis of 
IL-1α in plasma, which is one of the most important 
pro-inflammatory cytokines. IL-1α is secreted by mono-
cytes/macrophages activated via TNFα and/or bacterial 
endotoxin. Furthermore, IL1-α markedly potentiates the 
toxic effect of TNFα in animal experiments (Waage et 
al., 1991). Rheumatoid arthritis is associated with elevat-
ed levels of IL-1 in the synovium. IL-1 is closely related 
to inflammation and articular damage in several arthritis 
models and it is therefore generally accepted that IL-1 
has a pivotal role in the pathophysiology of rheuma-
toid arthritis. In particular, IL-1 is a potent stimulator 
of synoviocytes, chondrocytes and osteoblasts. Moreo-
ver, IL-1 is a key mediator of synovial inflammation and 
pannus formation (Dinarello & Moldawer, 2002). In the 
AA model used in our experiments, IL-1α was signifi-
cantly increased in plasma on day 14 and also on day 28 
(Bauerova et al., 2007; 2009). Figure 4 shows that the ef-
fects of the given treatments on the AA-increased IL-1α 
levels are very close to the effects illustrated in Figs. 1 
and 2. The improving effect on the increased cytokine 
plasmatic levels is rising in the order CoQ10, MTX and 
CoQ10+MTX. Furthermore, a statistically significant dif-
ference was found between MTX monotherapy and its 
combination with CoQ10.
Activity of GGT in selected tissues
As the only enzyme of the γ-glutamyl cycle lo-
cated on the outer surface of the plasma membrane, 
γ-glutamyltransferase (GGT) plays a key role in glutath-
ione (GSH) homeostasis by breaking down extracellular 
GSH and providing cysteine, the rate limiting substrate 
for intracellular de novo synthesis of GSH (Zhang et al., 
2005). Moreover, GGT is a multifunctional protein. 
There is evidence that cellular GGT plays an impor-
tant role in the antioxidant defense system (Kugelman 
et al., 1994; Lieberman et al., 1996). Ectoplasmic GGT 
favors the cellular supply of GSH, the most important 
non-protein antioxidant of the cell. Some epidemiologi-
cal studies have suggested that serum GGT within its 
normal range might be an early marker of oxidative 
stress (Lee & Jacobs, 2005) as well as of the activation 
of systemic inflammation (Yamada et al., 2006). GGT 
activity in organs such as spleen and joint could be a 
simple and inexpensive marker of AA and RA develop-
Figure 3. Levels of CoQ9 in plasma determined in the model of 
adjuvant arthritis on day 28
Effects of CoQ10 and methotrexate in monotherapy and com-
bined therapy on plasma concentration of CoQ9. The data were 
expressed as arithmetic mean ± S.E.M. Each group contained 8–10 
animals. Statistical significance was evaluated applying Student’s 
t-test for independent variables: **P < 0.01 with respect to control 
healthy animals; +P < 0.05 with respect to untreated arthritic ani-
mals.
Figure 4. Levels of IL-1α in plasma determined in the model of 
adjuvant arthritis on day 28.
Effects of CoQ10 and methotrexate in monotherapy and combined 
therapy on plasma concentration of IL-1α. The data were ex-
pressed as arithmetic mean ± S.E.M. Each group contained 8–10 
animals. Statistical significance was evaluated applying Student’s 
t-test for independent variables: **P < 0.01 with respect to control 
healthy animals; ++P < 0.01 with respect to untreated arthritic ani-
mals; ##P < 0.01 for comparison of methotrexate monotherapy with 
combined therapy.
Figure 5. GGT activities in spleen homogenates of rats 28 days 
after arthritis induction
Effects of CoQ10 and methotrexate in monotherapy and combined 
therapy on the activities of GGT in the spleen. 4-NA: 4-nitroaniline. 
The data were expressed as arithmetic mean ± S.E.M. Each group 
contained 8–10 animals. Statistical significance was evaluated ap-
plying Student’s t-test for independent variables: ***P < 0.001 with 
respect to control healthy animals; +++P < 0.001 with respect to un-
treated arthritic animals.
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ment both at the systemic and local level (Bauerova et 
al., 2006). Figure 5 shows the change in GGT activity 
in spleen homogenate, which could be described as a 
systemic inflammatory marker. Arthritis increases GGT 
activity, which was found to be three times higher than 
in HC. MTX decreased the increased activity back to 
the control value. Although monotherapy with CoQ10 
was without effect on this parameter, the combination 
therapy returned the GGT activity to control level of 
healthy animals. For the local inflammatory parameter 
— the activity of GGT in joint homogenate — an 
approximately double increase was recorded on com-
paring arthritic animals with HC (Fig. 6). The treated 
groups presented the same results as shown in Fig. 4. 
These findings suggest that the cycles of GGT and 
CoQ are not directly coupled.
The functionality of peripheral blood neutrophils in 
adjuvant arthritis affected by evaluated treatment
Neutrophils, also known as polymorphonuclear leu-
kocytes (PMNs) or phagocyting cells, play a vital role 
within the immune system. The processes of phago-
cytosis and the subsequent production of reactive 
oxygen intermediates during oxidative burst are cru-
cial components of the host defense system. Appar-
ently, neutrophils exhibit many of the properties of 
phagocytotic cells of the monocyte/macrophage line-
age. Neutrophils are present in a number of chronic 
inflammatory diseases, such as arthritis, and this is 
indicative of their important role in chronic inflam-
mation. Their rapid secretion of different factors, re-
leased also by macrophages, lymphocytes and fibrob-
lasts, indicates that neutrophils can play similar roles 
in chronic inflammation. Many of these factors are 
pivotal in causing tissue destruction, either directly or 
indirectly (Edwards & Hallett, 1997; Haynes, 2007). 
Recent data have revealed that RA-derived peripheral 
and synovial fluid neutrophils develop an intense res-
piratory burst (Cascao et al., 2010). In the model of 
AA, we observed already on experimental day 7 that 
AA was accompanied by an increased number of neu-
trophils in blood and by a more pronounced sponta-
neous as well as phorbol myristate acetate-stimulated 
chemiluminescence (Nosal et al., 2007). Interestingly, 
increased production of ROS by neutrophils emerged 
already in an early phase of disease, therefore we de-
cided to investigate this finding more precisely using 
flow cytometry. Another reason was that the changes 
in neutrophils occur before the clinical parameter HPV 
starts to be increased. The functionality of peripheral 
blood neutrophils in AA was evaluated by phagocy-
tosis, oxidative burst and metabolic activity (Fig. 7). 
Both phagocytosis and oxidative burst were increased 
due to arthritis. Metabolic activity of neutrophils is 
the percentage of double positive cells — simultane-
ously phagocytotic and positive for oxidative burst. 
Decreased metabolic activity could be explained with 
increased number of “arthritic” neutrophils, which are 
positive only for oxidative burst and therefore are not 
counted as double positive cells. The immunosuppres-
sive effect of MTX was demonstrated in lowering all 
parameters, not only in comparison with arthritis but 
also with HC. The addition of CoQ10 to MTX modu-
lated all processes back to the level of HC. The ob-
served immunoenhancing activity of CoQ10 may prove 
beneficial in MTX routine treatment. In this experi-
ment, flow cytometric determination of the function-
ality of neutrophils was first applied for an adjuvant 
arthritis experimental model on rats.
In summary, we found that CoQ10 could potentiate 
both the antiarthritic (decrease of hind paw volume) 
and the antioxidant effect of methotrexate on the lev-
el of oxidation of proteins (suppression of levels of 
protein carbonyls in plasma) as well as lipoperoxida-
tion (suppression of levels of HNE adducts and MDA 
adducts to plasma proteins). Further, the same effect 
was observed for plasmatic levels of CoQ9 and IL-1α, 
partially also for γ-glutamyltransferase activity assessed 
in joints and spleen. Moreover, the combination ther-
apy improved the functionality of peripheral blood 
neutrophils in AA, with a balancing effect on the im-
munosuppression caused by MTX monotherapy. 
In conclusion, combined administration of CoQ10 
and methotrexate suppressed arthritic progression in 
rats more effectively than did MTX alone. This find-
ing may become a beneficial contribution to the treat-
ment of rheumatoid arthritis. Restoration of redox im-
balance in chronic inflammatory diseases may be of 
significant importance in new therapeutic strategies. 
Figure 6. Activities of GGT in hind paw joint homogenate de-
termined in the model of adjuvant arthritis on day 28
Effects of CoQ10 and methotrexate in monotherapy and combined 
therapy on the activities of GGT in the joint. 4-NA: 4-nitroaniline. 
The data were expressed as arithmetic mean ± S.E.M. Each group 
contained 8–10 animals. Statistical significance was evaluated ap-
plying Student’s t-test for independent variables: ***P < 0.001 with 
respect to control healthy animals; +++P < 0.001 with respect to un-
treated arthritic animals.
Figure 7. Functionality of peripheral blood neutrophils deter-
mined on day 7 of adjuvant arthritis
Effects of CoQ10 and methotrexate in monotherapy and com-
bined therapy on phagocytosis, oxidative burst and metabolic 
activity of peripheral blood neutrophils. Phagocytic activity, oxi-
dative burst and metabolic activity were expressed as percentage 
of neutrophils actually undergoing these processes in popula-
tion of 5000 neutrophils. The data were expressed as arithmetic 
mean ± S.E.M. Each group contained 8–10 animals. Statistical sig-
nificance was evaluated applying Student’s t-test for independ-
ent variables: ***P < 0.05 with respect to control healthy animals; 
++P < 0.01 with respect to untreated arthritic animals. #P < 0.05 and 
##P < 0.01 for comparison of methotrexate monotherapy with com-
bined therapy.
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